Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3 Pyridinecarboxamide
2. 3-pyridinecarboxamide
3. B 3, Vitamin
4. B3, Vitamin
5. Enduramide
6. Jenapharm, Nicotinsureamid
7. Niacinamide
8. Nicobion
9. Nicotinsureamid Jenapharm
10. Papulex
11. Vitamin B 3
12. Vitamin B3
13. Vitamin Pp
1. Niacinamide
2. 98-92-0
3. 3-pyridinecarboxamide
4. Pyridine-3-carboxamide
5. Nicotinic Acid Amide
6. Vitamin Pp
7. Papulex
8. Aminicotin
9. Amixicotyn
10. Nicobion
11. Nicotylamide
12. Nikotinamid
13. Savacotyl
14. Benicot
15. Dipegyl
16. Endobion
17. Hansamid
18. Pelmine
19. Nicotinic Amide
20. Delonin Amide
21. Pelonin Amide
22. Vi-nicotyl
23. Austrovit Pp
24. Inovitan Pp
25. Nicosylamide
26. Nicotilamide
27. Nicotililamido
28. Amnicotin
29. Niacevit
30. Nicamina
31. Nicamindon
32. Nicofort
33. Nicomidol
34. Nicotamide
35. Nicovitina
36. Nicovitol
37. Nicozymin
38. Niocinamide
39. Niozymin
40. Niamide
41. Nicasir
42. Nicogen
43. Nicota
44. Nicotol
45. Nicovit
46. Niko-tamin
47. 3-carbamoylpyridine
48. Nicotine Acid Amide
49. Nandervit-n
50. Pyridine-3-carboxylic Acid Amide
51. Vitamin B
52. Niavit Pp
53. Nicotinamidum
54. Nicosan 2
55. Nicotine Amide
56. Beta-pyridinecarboxamide
57. Nikotinsaeureamid
58. Nicotylamidum
59. Mediatric
60. Nicotinsaureamid
61. Pyridine, 3-carbamoyl-
62. 3-pyridinecarboxylic Acid Amide
63. M-(aminocarbonyl)pyridine
64. Acid Amide
65. Factor Pp
66. Nicotinamida
67. Nicovel
68. Vitamin B (van)
69. Pelmin
70. Amid Kyseliny Nikotinove
71. Witamina Pp
72. Pp-faktor
73. Amide Pp
74. Nicotinsaureamid [german]
75. Nikotinsaeureamid [german]
76. Amid Kyseliny Nikotinove [czech]
77. Nicotinamidum [inn-latin]
78. Nicotinamida [inn-spanish]
79. Nam
80. Niacinamid
81. Nictoamide
82. Ccris 1901
83. Dipigyl
84. Hsdb 1237
85. Vi-noctyl
86. Ai3-02906
87. Nsc 13128
88. B-pyridinecarboxamide
89. Niacinamide [usp]
90. Nicotinamide [inn]
91. 3-(aminocarbonyl)pyridine
92. Mfcd00006395
93. Nsc-13128
94. Nsc-27452
95. .beta.-pyridinecarboxamide
96. Nicotinamide (vitamin B3)
97. Chembl1140
98. Mls000069714
99. Chebi:17154
100. 25x51i8rd4
101. Nsc13128
102. Niacinamide (usp)
103. Ncgc00093354-03
104. Ncgc00093354-05
105. Smr000058212
106. Nicotinamide 10 Microg/ml In Acetonitrile
107. Dsstox_cid_929
108. Niacinamide;nicotinic Acid Amide;vitamin B3
109. Wln: T6nj Cvz
110. Dsstox_rid_75873
111. Dsstox_gsid_20929
112. Niacinamide [usan]
113. Enduramide
114. Cas-98-92-0
115. B3, Vitamin
116. Vitamin B 3
117. B 3, Vitamin
118. 3 Pyridinecarboxamide
119. Sr-01000721872
120. Nicotinsaureamid Jenapharm
121. Einecs 202-713-4
122. Jenapharm, Nicotinsaureamid
123. Niacotinamide
124. Nicotinamid
125. Nicotin-amide
126. Unii-25x51i8rd4
127. Nicotinsaeureamid
128. 3-amidopyridine
129. Dea No. 1405
130. Nicotinamide,(s)
131. Vitamin B3 Amide
132. 3-yridinecarboxamide
133. Mediatric (salt/mix)
134. Niacin - Vitamin B3
135. 1yc5
136. Opera_id_775
137. Niacin (as Niacinamide)
138. Niacinamide [ii]
139. Niacinamide(vitamin B3)
140. Niacinamide [fcc]
141. Nicotinamide [mi]
142. Niacinamide [hsdb]
143. Niacinamide [inci]
144. Nicotinamide [jan]
145. Bmse000281
146. Molmap_000061
147. Ec 202-713-4
148. Niacinamide [vandf]
149. Schembl2926
150. Nicotinamide (jp17/inn)
151. Nicotinamidum [hpus]
152. Niacinamide [usp-rs]
153. Nicotinamide [mart.]
154. Mls001424246
155. Nicotinamide [who-dd]
156. Nicotinamide [who-ip]
157. Nicotinamide-(amide-[15n])
158. Schembl6278767
159. Sgcut00176
160. Zinc5878
161. Tpn Component Niacinamide
162. Dtxsid2020929
163. Schembl19978192
164. Bdbm27507
165. Niacinamide [orange Book]
166. Nicotinamide, Niacin, Vitamin B3
167. Hms2052m21
168. Hms2090b05
169. Hms2093h03
170. Hms2236j03
171. Hms3370f21
172. Hms3394m21
173. Hms3655m20
174. Hms3713b22
175. Hms3884a16
176. Nicotinamide [ep Impurity]
177. Pharmakon1600-01505397
178. Niacinamide [usp Monograph]
179. Nicotinamide [ep Monograph]
180. Bcp07322
181. Hy-b0150
182. Niacinamide Component Of Tpn
183. Nicotinamide (vitamin B3) Solution
184. Nsc27452
185. To_000073
186. Nicotinamide 1.0 Mg/ml In Methanol
187. Nicotinamide, >=98.5% (hplc)
188. Nicotinamide, >=99.5% (hplc)
189. Tox21_111202
190. Tox21_201716
191. Tox21_302776
192. Nicotinamidum [who-ip Latin]
193. Nsc759115
194. S1899
195. Stl163867
196. Akos005715850
197. Tox21_111202_1
198. Ccg-101149
199. Cs-1968
200. Db02701
201. Nc00399
202. Nsc-759115
203. Sb74497
204. Nicotinamide 100 Microg/ml In Methanol
205. Nicotinamide, >=98% (hplc), Powder
206. Ncgc00093354-04
207. Ncgc00093354-06
208. Ncgc00093354-09
209. Ncgc00256432-01
210. Ncgc00259265-01
211. Niacin (as Niacinamide) [vandf]
212. As-13845
213. Bn166252
214. Nicotinamide, Puriss., 99.0-101.0%
215. Sy024804
216. Nicotinamide, Tested According To Ph.eur.
217. Sbi-0206826.p001
218. Db-057754
219. Ft-0631517
220. Ft-0672696
221. Ft-0773644
222. N0078
223. N1651
224. Sw197779-3
225. En300-15612
226. Niacinamide, Meets Usp Testing Specifications
227. C00153
228. D00036
229. Nicotinamide (niacinamide), Analytical Standard
230. Ab00373895-13
231. Ab00373895_15
232. Ab00373895_16
233. Nicotinamide, Vetec(tm) Reagent Grade, >=98%
234. A845925
235. Ac-907/25014114
236. Q192423
237. Q-201470
238. Sr-01000721872-3
239. Sr-01000721872-4
240. Sr-01000721872-5
241. Z33546463
242. F2173-0513
243. Niacinamide;nicotinic Acid Amide;vitamin B3; Vitamin Pp
244. Nicotinamide, British Pharmacopoeia (bp) Reference Standard
245. A186b02e-6c70-4e54-9739-79398d439aaa
246. Nicotinamide, European Pharmacopoeia (ep) Reference Standard
247. Niacinamide, United States Pharmacopeia (usp) Reference Standard
248. Niacinamide, Pharmaceutical Secondary Standard; Certified Reference Material
249. Nicotinamide, Bioreagent, Suitable For Cell Culture, Suitable For Insect Cell Culture
250. Nicotinamide (vitamin B3) Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 122.12 g/mol |
|---|---|
| Molecular Formula | C6H6N2O |
| XLogP3 | -0.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 122.048012819 g/mol |
| Monoisotopic Mass | 122.048012819 g/mol |
| Topological Polar Surface Area | 56 Ų |
| Heavy Atom Count | 9 |
| Formal Charge | 0 |
| Complexity | 114 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Vitamin B Complex
National Library of Medicine's Medical Subject Headings. Niacinamide. Online file (MeSH, 2018). Available from, as of June 1, 2018: https://www.nlm.nih.gov/mesh/2017/mesh_browser/MBrowser.html
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Nicotinamide is included in the database.
NIH/NLM; ClinicalTrials.Gov. Available from, as of June 1, 2018: https://clinicaltrials.gov/
Niacin and niacinamide are used to prevent niacin deficiency and to treat pellagra. Some clinicians prefer niacinamide for the treatment of pellagra because it lacks vasodilating effects. Pellagra may result from dietary deficiency, isoniazid therapy, or from decreased conversion of tryptophan to niacin in Hartnup disease or carcinoid tumors. /Included in US product label/
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017
Although niacin and niacinamide have not been shown by well-controlled trials to have therapeutic value, the drugs have been used for the management of schizophrenic disorder, drug-induced hallucinations, chronic brain syndrome, hyperkinesis, unipolar depression, motion sickness, alcohol dependence, livedoid vasculitis, acne, and leprosy. /NOT included in US product label/
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017
For more Therapeutic Uses (Complete) data for Nicotinamide (14 total), please visit the HSDB record page.
Blood glucose concentration should be monitored periodically in patients receiving niacin or niacinamide, especially early in the course of therapy. Dosage requirements for antidiabetic agents (e.g., insulin, oral sulfonylureas) may change in diabetic patients.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017
Potential adverse effects on fetus: Higher levels in fetus than mother, but no fetal anomalies reported. Potential side effects on breast-fed infant: No adverse effects known . FDA Category: C (C = Studies in laboratory animals have revealed adverse effects on the fetus (teratogenic, embryocidal, etc.), but there are no controlled studies in pregnant women. The benefits from use of the drug in pregnant women may be acceptable despite its potential risks, or there are no laboratory animal studies or adequate studies in pregnant women.) /from table II/
Stockton, D.L. and A.S. Paller. J Am Acad Dermatol 23 (1):87-103 (1990)
Niacinamide /was administered/ daily as a liquid formulation to head and neck cancer patients receiving a 5- to 7-week course of radiotherapy. Niacinamide was administered orally 1.5 hr before irradiation. The daily dose was 80 mg/kg bw to a maximum of 6 g. A dose reduction to 60 mg/kg was introduced for patients with severe side-effects. ... Side-effects of niacinamide were monitored. In all patients, peak concentrations greater than 700 nM/mL could be obtained 0.25-3 hr after drug intake. During the first week of treatment, plasma concentrations at the time of irradiation were adequate in 82% of the samples. Nausea, with or without vomiting, occurred in 65% of patients. Tolerance improved after a 25% reduction of the dose in six of seven patients but plasma concentrations at the time of irradiation decreased below 700 nM/mL in four out of six patients. Other niacinamide side effects included gastrointestinal symptoms, flushing, dizziness, sweating, fatigue, and headache. The most powerful single predictor for severe niacinamide toxicity was the mean of the plasma concentration measured at the time of irradiation during the first week.
Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin p.6; Intl J of Toxicology 24 (Suppl 5): 1-31 (2005). Available from, as of June 4, 2018: https://www.cir-safety.org/ingredients
Abnormal liver function test results (including increased serum concentrations of bilirubin, AST [SGOT], ALT [SGPT], and LDH), jaundice, and chronic liver damage have occurred during niacin and niacinamide therapy. Abnormal prothrombin time and hypoalbuminemia have also been reported.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017
For more Drug Warnings (Complete) data for Nicotinamide (6 total), please visit the HSDB record page.
Vitamin B Complex
A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)
A11HA01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A11 - Vitamins
A11H - Other plain vitamin preparations
A11HA - Other plain vitamin preparations
A11HA01 - Nicotinamide
14(C)Niacinamide was incorporated into an oil-in-water (o/w) skin cream and into a 30% (w/w) soap base and applied to the skin of female Colworth Wistar rats. The final concentration of niacinamide in the soap solution was approximately 0.3% (w/v) and was 1% (w/w) in the skin cream. Application of the skin cream and soap paste was made to rat skin at approximately 20 mg/sq cm. The cream was carefully massaged over 10 sq cm of skin for up to 5 min before covering with polythene-lined occlusive protective patches. The rats were placed in metabolism cages for 48 hr during which time all excreta was collected. At 48 hr, the animals were killed and the patch, carcass, and treated area of skin were assayed for 14(C). Up to 32% 14(C) was recovered in excreta and in the carcasses from rats treated with skin cream containing 14(C)Niacinamide and up to 30% from those treated with soap paste.
Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin p.5; Intl J of Toxicology 24 (Suppl 5): 1-31 (2005). Available from, as of June 4, 2018: https://www.cir-safety.org/ingredients
Nicotinamide is efficiently absorbed from the gastrointestinal tract. At low doses, absorption is mediated via sodium-dependent facilitated diffusion. Passive diffusion is the principal mechanism of absorption at higher doses. Doses of up to three to four grams of nicotinamide are almost completely absorbed. Nicotinamide is transported via the portal circulation to the liver and via the systemic circulation to the various tissues of the body. Nicotinamide enters most cells by passive diffusion and enters erythrocytes by facilitated transport.
PDR for Nutritional Supplements 2nd ed. Thomson Reuters, Montvale, NJ 2008, p. 452
Niacinamide is widely distributed /throughout/ body tissues.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017
Niacin and niacinamide are readily absorbed from the GI tract following oral administration, and niacinamide (no longer commercially available in the US) is readily absorbed from subcutaneous and IM injection sites.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017
For more Absorption, Distribution and Excretion (Complete) data for Nicotinamide (16 total), please visit the HSDB record page.
In amounts needed for physiologic function as a coenzyme (12-18 mg daily), niacin is converted to niacinamide; larger doses of niacin are converted to niacinamide to only a minor degree. Niacinamide is metabolized in the liver to N-methylniacinamide, other N-methylated derivatives, and nicotinuric acid (the glycine conjugate of niacin). These metabolites are excreted in urine. Following administration of physiologic doses of niacin or niacinamide, only a small amount of niacinamide is excreted unchanged in urine; however, following administration of larger doses, a greater proportion of niacin and niacinamide is excreted unchanged.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017
N1-Methyl-4-pyridone-3-carboxamide was detected on chromatograms of plasma extracts after oral administration of niacinamide to two human subjects.
Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin p.6; Intl J of Toxicology 24 (Suppl 5): 1-31 (2005). Available from, as of June 4, 2018: https://www.cir-safety.org/ingredients
6-Hydroxynicotinamide and 6-hydroxynicotinic acid /were detected/ as urinary metabolites by comparison of ultraviolet, infrared, and mass spectra following intraperitoneal injections of 14(C)Niacin or 14(C)Niacinamide into rats.
Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin p.8; Intl J of Toxicology 24 (Suppl 5): 1-31 (2005). Available from, as of June 4, 2018: https://www.cir-safety.org/ingredients
N1-methyl-4- pyridone-3-carboxamide is a major metabolite of niacin and niacinamide which has been found to be synthesized from N1- methylnicotinamide.
Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin p.8; Intl J of Toxicology 24 (Suppl 5): 1-31 (2005). Available from, as of June 4, 2018: https://www.cir-safety.org/ingredients
For more Metabolism/Metabolites (Complete) data for Nicotinamide (7 total), please visit the HSDB record page.
The mean half life values were 2.7 hr, 5.9 hr, and 8.1 hr after taking 1, 3, or 6 g of Niacinamide, respectively.
Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin p.6; Intl J of Toxicology 24 (Suppl 5): 1-31 (2005). Available from, as of June 4, 2018: https://www.cir-safety.org/ingredients
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
NDC Package Code : 51552-0771
Start Marketing Date : 1998-04-01
End Marketing Date : 2026-06-27
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 38779-3303
Start Marketing Date : 2023-11-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63238-3600
Start Marketing Date : 2018-03-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57845-1007
Start Marketing Date : 2021-03-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 10695-308
Start Marketing Date : 2025-05-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 83511-010
Start Marketing Date : 2024-12-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - FOR SOLUTION;INTRAVENOUS - 80MG/VIAL...DOSAGE - FOR SOLUTION;INTRAVENOUS - 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL
USFDA APPLICATION NUMBER - 18920
DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/...DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML
USFDA APPLICATION NUMBER - 21163
DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/...DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML
USFDA APPLICATION NUMBER - 21163
DOSAGE - INJECTABLE;INTRAVENOUS - 200MG/VIAL;...DOSAGE - INJECTABLE;INTRAVENOUS - 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL
USFDA APPLICATION NUMBER - 21625
DOSAGE - INJECTABLE;INJECTION - 20MG/ML;0.006...DOSAGE - INJECTABLE;INJECTION - 20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML
USFDA APPLICATION NUMBER - 8809
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kewpie Corporation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Capital Farma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Avesta Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]BioSpectra
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Doshion Polyscience
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Hayashibara
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nippon Fine Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shandong Focus Biotechnology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Symrise
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]TopChem Pharmaceuticals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Topical
Parenteral
Thickeners and Stabilizers
Solubilizers
Coating Systems & Additives
Taste Masking
Direct Compression
Emulsifying Agents
Granulation
Disintegrants & Superdisintegrants
Film Formers & Plasticizers
Controlled & Modified Release
Surfactant & Foaming Agents
Lubricants & Glidants
Chewable & Orodispersible Aids
Rheology Modifiers
Co-Processed Excipients
API Stability Enhancers
Empty Capsules
Coloring Agents
Vegetarian Capsules
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
52
PharmaCompass offers a list of Nicotinamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nicotinamide manufacturer or Nicotinamide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nicotinamide manufacturer or Nicotinamide supplier.
PharmaCompass also assists you with knowing the Nicotinamide API Price utilized in the formulation of products. Nicotinamide API Price is not always fixed or binding as the Nicotinamide Price is obtained through a variety of data sources. The Nicotinamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Niacinamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Niacinamide, including repackagers and relabelers. The FDA regulates Niacinamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Niacinamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Niacinamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Niacinamide supplier is an individual or a company that provides Niacinamide active pharmaceutical ingredient (API) or Niacinamide finished formulations upon request. The Niacinamide suppliers may include Niacinamide API manufacturers, exporters, distributors and traders.
click here to find a list of Niacinamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Niacinamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Niacinamide active pharmaceutical ingredient (API) in detail. Different forms of Niacinamide DMFs exist exist since differing nations have different regulations, such as Niacinamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Niacinamide DMF submitted to regulatory agencies in the US is known as a USDMF. Niacinamide USDMF includes data on Niacinamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Niacinamide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Niacinamide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Niacinamide Drug Master File in Japan (Niacinamide JDMF) empowers Niacinamide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Niacinamide JDMF during the approval evaluation for pharmaceutical products. At the time of Niacinamide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Niacinamide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Niacinamide Drug Master File in Korea (Niacinamide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Niacinamide. The MFDS reviews the Niacinamide KDMF as part of the drug registration process and uses the information provided in the Niacinamide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Niacinamide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Niacinamide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Niacinamide suppliers with KDMF on PharmaCompass.
A Niacinamide CEP of the European Pharmacopoeia monograph is often referred to as a Niacinamide Certificate of Suitability (COS). The purpose of a Niacinamide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Niacinamide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Niacinamide to their clients by showing that a Niacinamide CEP has been issued for it. The manufacturer submits a Niacinamide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Niacinamide CEP holder for the record. Additionally, the data presented in the Niacinamide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Niacinamide DMF.
A Niacinamide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Niacinamide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Niacinamide suppliers with CEP (COS) on PharmaCompass.
A Niacinamide written confirmation (Niacinamide WC) is an official document issued by a regulatory agency to a Niacinamide manufacturer, verifying that the manufacturing facility of a Niacinamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Niacinamide APIs or Niacinamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Niacinamide WC (written confirmation) as part of the regulatory process.
click here to find a list of Niacinamide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Niacinamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Niacinamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Niacinamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Niacinamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Niacinamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Niacinamide suppliers with NDC on PharmaCompass.
Niacinamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Niacinamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Niacinamide GMP manufacturer or Niacinamide GMP API supplier for your needs.
A Niacinamide CoA (Certificate of Analysis) is a formal document that attests to Niacinamide's compliance with Niacinamide specifications and serves as a tool for batch-level quality control.
Niacinamide CoA mostly includes findings from lab analyses of a specific batch. For each Niacinamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Niacinamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Niacinamide EP), Niacinamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Niacinamide USP).
